Advertisement
YOU ARE HERE: LAT HomeCollectionsShionogi Co
IN THE NEWS

Shionogi Co

FEATURED ARTICLES
BUSINESS
February 21, 1992 | From Times Staff and Wire Reports
Lilly, Japanese Firm to Swap Product Rights: Eli Lilly and Co. said it will transfer its capsule manufacturing business to Japan's Shionogi & Co. The agreement will give Shionogi ownership of Lilly's Qualicaps operations in Japan, the United States and other countries. Osaka-based Shionogi will make an undisclosed payment to Lilly and transfer to Lilly the marketing rights to the insulin medicine Humulin in Japan.
ARTICLES BY DATE
BUSINESS
February 21, 1992 | From Times Staff and Wire Reports
Lilly, Japanese Firm to Swap Product Rights: Eli Lilly and Co. said it will transfer its capsule manufacturing business to Japan's Shionogi & Co. The agreement will give Shionogi ownership of Lilly's Qualicaps operations in Japan, the United States and other countries. Osaka-based Shionogi will make an undisclosed payment to Lilly and transfer to Lilly the marketing rights to the insulin medicine Humulin in Japan.
Advertisement
BUSINESS
March 7, 1989 | GREG JOHNSON, Times Staff Writer
Molecular Biosystems has signed over marketing rights for its Albunex product in Japan, South Korea and Taiwan to Shionogi & Co., one of Japan's largest pharmaceutical concerns, in a deal valued at $31 million, the firms said Monday. Molecular Biosystems will receive $10 million of that total when the agreement is executed. This is the third distribution agreement signed by Molecular Biosystems in recent months. Earlier, San Diego-based Molecular Biosystems signed over U. S.
Los Angeles Times Articles
|